title: Effect of terfenadine on TNF alpha release from peripheral blood mononuclear cells during cow's milk allergy.
abstract: BACKGROUND
  In infants with cow's milk allergy and intestinal symptoms, peripheral blood mononuclear cells stimulated in vitro with cow's milk proteins, secrete large amounts of the proinflammatory cytokine TNF alpha thus altering intestinal barrier capacity. Terfenadine, an antihistaminic drug, inhibits the release of several inflammatory mediators, including histamine, prostaglandins and leukotrienes.
  
  
  OBJECTIVE
  To test the potential ability of terfenadine to inhibit TNF alpha secretion by mononuclear cells from infants with cow's milk allergy.
  
  
  METHODS
  Mononuclear cells from infants allergic to cow's milk proteins were stimulated in vitro for 6 days by a mixture of milk proteins (beta-lactoglobulin, alpha-lactalbumin and casein) with or without terfenadine (0.1-1 microM) and culture supernatants were assayed for TNF alpha by enzyme immunoassay. The effect of culture supernatants on intestinal barrier capacity was evaluated by measuring the electrical resistance (index of integrity) of filter-grown HT29-19 A intestinal cells in Ussing chambers.
  
  
  RESULTS
  During active cow's milk allergy, mononuclear cells stimulated with cow's milk proteins secreted large amounts of TNF alpha which significantly reduced the electrical resistance of HT29-19 A intestinal cells. There was a dose-dependent decrease in TNF alpha secretion in the presence of terfenadine, with a maximal inhibition of 62% of this secretion at 1 microM. Accordingly, terfenadine-treated mononuclear cells supernatants did not alter the electrical resistance of intestinal HT29.19 A cells.
  
  
  CONCLUSIONS
  These results indicate that in infants with intestinal dysfunction due to cow's milk allergy, terfenadine is a potent inhibitor of the TNF alpha secretion induced by sensitizing milk protein antigens. This inhibition prevents the degradation of intestinal function as measured in an intestinal cell line, in vitro.
authors.affiliation: INSERM U290, Hôpital St-Lazare, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Benlounes
authors.forename: C
authors.initials: C
authors.lastname: Dupont
authors.forename: C
authors.initials: C
authors.lastname: Candalh
authors.forename: M A
authors.initials: MA
authors.lastname: Blaton
authors.forename: M
authors.initials: M
authors.lastname: Bloom
authors.forename: M
authors.initials: M
authors.lastname: Heyman
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D017097:Electric Impedance; D019073:HT29 Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D016269:Milk Hypersensitivity / Q000097:blood* / Q000378:metabolism; D008894:Milk Proteins / Q000494:pharmacology; D016593:Terfenadine / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D018926:Anti-Allergic Agents; D017077:Culture Media, Conditioned; D008894:Milk Proteins; D014409:Tumor Necrosis Factor-alpha; D016593:Terfenadine